Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy

• ClinicalTrials.gov Identifier: NCT03946618
• Recruitment Status: Recruiting
• First Posted: May 10, 2019
• Last Update Posted: January 6, 2021
• Sponsor: Mayo Clinic
• Collaborators: National Institute of Neurological Disorders and Stroke (NINDS); Medtronic
• Information provided by (Responsible Party): Gregory Worrell, Mayo Clinic

Study Description

Brief Summary:

Researchers are trying to determine if tracking seizure occurrence, seizure probability, behavioral state, cognition, and mood can be achieved using an implantable brain sensing and stimulation device (Medtronic RC+S Summit) coupled to an external, handheld, patient assistant device (PAD) with capability for patient interaction (patient data input). The system (RC+S & PAD) provides intracranial EEG (iEEG) sensing, electrical brain stimulation, and machine learning algorithms running on the RC+S and PAD that will be coupled with electrical brain stimulation (EBS) to prevent seizures and improve quality of life in patients with epilepsy.

Condition or disease	Intervention/treatment	Phase
Epilepsy	Device: Medtronic Summit System, Olympus	Phase 1

Detailed Description:

This study will include patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy. The plan is to have 10 patients take part in this study at Mayo Clinic Rochester.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Epilepsy
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Human Safety and Feasibility Study of Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy
• Actual Study Start Date: July 10, 2019
• Estimated Primary Completion Date: April 30, 2022
• Estimated Study Completion Date: December 31, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Epilepsy; Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy	Device: Medtronic Summit System, Olympus; Electrical brain stimulation with an implantable pulse generator

Outcome Measures

Primary Outcome Measures :

1. Adverse events (AE) experienced with the RC+S system [ Time Frame: Through 15 months ]
   Number of AEs reported
2. 24/7 continuous iEEG monitoring [ Time Frame: Through 15 months ]
   Number of RC+S systems that generates continues 24/7 EEG without interruption
3. Change in mood [ Time Frame: Baseline, biweekly for up to 15 months ]
   Measured using daily mood and anxiety trackers questionnaire, where 1 is not at all and 7 is extremely
4. Change in anxiety [ Time Frame: Baseline, biweekly for up to 15 months ]
   Measured using anxiety Generalized Anxiety Disorder 7-item (GAD-7) scale, where 0 is not at all sure and 3 is nearly every day
5. Tracking cognition [ Time Frame: Baseline, biweekly for up to 15 months ]
   Measured using free recall task

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• Focal epilepsy, including seizures with and without impairment of consciousness, and secondarily generalized seizures:

  • Disabling seizure counts >3 per month (Disabling seizures are those with significant negative impact on the patients life)
  • Drug resistance to >2 appropriate seizure drugs with therapeutic serum concentrations
  • Not a good candidate for resective surgery or at significant risk for verbal memory decline as determined by our institution's multidisciplinary Epilepsy Surgery Committee.
  • For 3 months prior to enrollment, subject's anti-seizure medication dosages have been stable and subject has had at least 6 disabling (as defined in Inclusion Criteria 1) seizures per month, on average, with a seizure-free interval not to exceed 30 days. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster of seizures, for the purpose of this criterion, shall be considered a single seizure.
• With the exception of epilepsy, subject must be medically and neurologically stable.
• Mayo Clinic Epilepsy Surgery Committee approval for brain stimulation therapy obtained on clinical grounds and without reference to this protocol.
• Age 18 to 75
• Ability and willingness to provide informed consent and participate in the study protocol. Subject is able to interpret and to respond, in accordance with the study protocol, to the advisory indicators provided by the device.
• Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
• Subject can reasonably be expected to maintain a seizure diary alone or with the assistance of a competent individual.
• Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
• A female subject must have a negative serum pregnancy test within two weeks prior to entering the study, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
• Subject's seizure focus, based upon clinical semiology, intracranial electroencephalographic (iEEG) findings, and/or neuroimaging, shall demonstrate bilateral medial temporal lobe epilepsy or unilateral temporal lobe epilepsy of dominant temporal lobe origin.
• Subject has been informed of his or her eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
• Subject speaks and reads English.
• Subject has had a brain magnetic resonance imaging (MRI) epilepsy evaluation within the past two years.
• Subject has iEEG documentation of ictal events consistent with his or her predominant current seizure type.
• Subject's anatomy will permit implantation of the Medtronic Investigational RC+S generator within 20 mm of the skin surface.
• Subject can reasonably be expected to periodically check battery levels and recharge devices (Implanted neural stimulator (INS), Clinical Telemetry Module (CTM), and EPAD tablet) alone or with the assistance of a competent individual.

Exclusion Criteria

• For 3 months prior to enrollment, subject's anti-seizure medication dosages have not been stable, or subject has had more than 25 disabling (as defined in Inclusion Criteria 1) seizures per month, on average, or there was a seizure-free interval longer than 30 days within the past 3 months. Clinical seizures must be separated by a minimum of eight hours to not be considered part of a cluster. Cluster seizures are considered a single seizure event.
• Subject has a contraindication to magnetic resonance imaging.
• Subject has a substance abuse history (alcohol, prescription, or illicit medications) within the preceding two years.
• Subject participated in another drug or device trial within the preceding 30 days.
• Subject has been hospitalized for a psychiatric condition within the preceding two years or has had a history of psychosis within the preceding two years (excluding post-ictal psychosis).
• Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the RC+S device. This includes, but is not limited to, direct brain neurostimulators, spinal cord stimulators, vagus nerve stimulators (VNS), and cochlear implants. Patients with a vagus nerve stimulator implanted but turned off through the duration of the study may be enrolled, provided their clinical status has been stable for at least one month with VNS turned off. Alternatively, patients with a VNS may have the previously disabled VNS removed at time of surgery to implant the Medtronic RC+S.
• Subject has been diagnosed with psychogenic or non-epileptic seizures.
• Subject has been diagnosed with primary generalized seizures.
• Subject has experienced unprovoked status epilepticus in the preceding year.
• Subject has had therapeutic surgery to treat epilepsy that may interfere with electrode placement.
• Subject is on anticoagulants and is unable to discontinue them peri-surgically, as required by the neurosurgeon or Investigator.
• Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
• Subject is ineligible for cranial surgery.
• Pregnancy

Contacts and Locations

Contacts

Contact: Karla Crockett; 507-538-9140; crockett.karla@mayo.edu

Locations

United States, Minnesota

Mayo Clinic in Rochester; Recruiting

Rochester, Minnesota, United States, 55905

Contact: Karla Crockett 507-538-9140 crockett.karla@mayo.edu

Sponsors and Collaborators

Mayo Clinic

National Institute of Neurological Disorders and Stroke (NINDS)

Medtronic

Investigators

• Principal Investigator: Gregory A Worrell; Mayo Clinic

More Information

Additional Information:

Mayo Clinic Clinical Trials 

• Responsible Party: Gregory Worrell, Principal Investigator, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03946618
• Other Study ID Numbers: 18-005483; UH2NS095495-03 ( U.S. NIH Grant/Contract )
• First Posted: May 10, 2019
• Last Update Posted: January 6, 2021
• Last Verified: January 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:

Epilepsy; Epilepsies, Partial; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases